Medtronic (MDT) Offering Possible 9.17% Return Over the Next 8 Calendar Days

Medtronic’s most recent trend suggests a bullish bias. One trading opportunity on Medtronic is a Bull Put Spread using a strike $96.00 short put and a strike $91.00 long put offers a potential 9.17% return on risk over the next 8 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $96.00 by expiration. The full premium credit of $0.42 would be kept by the premium seller. The risk of $4.58 would be incurred if the stock dropped below the $91.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Medtronic is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Medtronic is bullish.

The RSI indicator is above 80 which suggests that the stock is in overbought territory.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Medtronic

Medtronic Delivers Favorable Outcome on Guardian Connect
Tue, 11 Jun 2019 12:39:12 +0000
Medtronic’s (MDT) data indicates that Guardian Connect will enable patients to better understand glucose trends and increase Time in Range.

See what the IHS Markit Score report has to say about Medtronic PLC.
Tue, 11 Jun 2019 12:07:53 +0000
Medtronic PLC NYSE:MDTView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for MDT with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MDT. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold MDT had net inflows of $5.04 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers’ Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

Real-World Data from Guardian(TM) Connect and Sugar.IQ(TM) Reveal Improved Diabetes Outcomes
Mon, 10 Jun 2019 21:47:00 +0000
June 10, 2019 – Medtronic plc (MDT), the global leader in medical technology, today announced real-world data on its Guardian(TM) Connect continuous glucose monitoring (CGM) system and Sugar.IQ(TM) diabetes assistant app presented at the 79th Scientific Sessions of the American Diabetes Association (ADA) Annual Meeting in San Francisco. The data presented were recorded by users of the Guardian Connect system paired with Sugar.IQ diabetes assistant, a separate first-of-its-kind intelligent app that continually analyzes how an individual`s glucose levels respond to food intake, insulin dosages, daily routines and other factors1. The Sugar.IQ app combines data from the Guardian Connect system with artificial intelligence technology from Medtronic`s strategic partner, IBM® Watson Health, to detect important patterns and trends for people with diabetes and help them make more informed decisions on how to better manage glucose levels and stay within target range.

Is Medtronic plc. (MDT) A Good Stock To Buy?
Mon, 10 Jun 2019 20:40:45 +0000
Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 750 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]

How The David Of Diabetes Devices Is Taking On Goliath — And Why Shares Dipped
Mon, 10 Jun 2019 16:55:38 +0000
Tandem Diabetes stock skidded Monday as investors questioned whether the medical devices maker could catch up to industry leader Medtronic in diabetes treatment using a pump and monitor.

Be Sociable, Share!

Related Posts